EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Exploring RNA therapeutics for urea cycle disorders

Eva Richard iD, Ainhoa Martínez-Pizarro, Lourdes R Desviat iD

Journal of Inherited Metabolic Disease · 2024-11 · 47 (6) · 1269-1277

DOI: 10.1002/jimd.12807 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 24.10.2024. Verfasst von Eva Richard und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Biología Molecular Severo Ochoa UAM-CSIC, IUBM, CIBERER, IdiPaz, Universidad Autónoma de Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Urea Cycle Disorders, Inborn, Genetic Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MICIU/AEI, ERDF, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA has triggered a significant shift in modern medicine, providing a promising way to revolutionize disease treatment methods. Different therapeutic RNA modalities have shown promise to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. Currently, there are 22 RNA‐based drugs approved for clinical use, including the COVID‐19 mRNA vaccines, whose unprecedented worldwide success has meant a definitive boost in the RNA research field. Urea cycle disorders (UCD), liver diseases with high mortality and morbidity, may benefit from the progress achieved, as different genetic payloads have been successfully targeted to liver using viral vectors, N‐acetylgalactosamine (GalNAc) conjugations or lipid nanoparticles (LNP). This review explores the potential of RNA‐based medicines for UCD and the ongoing development of applications targeting specific gene defects, enzymes, or transporters taking part in the urea cycle. Notably, LNP‐formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency, in the latter case has progressed to the clinical trials phase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urea Cycle Disorders, InbornGenetic TherapyHumansNanoparticlesCOVID-19RNA, MessengerAnimalsLiposomes

Stichwörter der Autor:innen

antisense oligonucleotidesmRNA therapyornithine transcarbamylase deficiencypseudoexonsplicingurea cycle

Substanzen

RNA, MessengerLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Centro de Biología Molecular Severo Ochoa UAM-CSIC, IUBM, CIBERER, IdiPaz, Universidad Autónoma de Madrid, Madrid, Spain.

ORCID-Profile: Eva Richard, Lourdes R Desviat

Förderung

  • MICIU/AEI
  • ERDF
  • European Regional Development Fund

Zitieren

APA

Richard, E., Martínez-Pizarro, A., & Desviat, L. R. (2024). Exploring RNA therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47(6), 1269-1277. https://doi.org/10.1002/jimd.12807

Vancouver

Richard E, Martínez-Pizarro A, Desviat LR. Exploring RNA therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease. 2024;47(6):1269-1277. doi:10.1002/jimd.12807

BibTeX
@article{Richard2024,
  author = {Richard, Eva and Martínez-Pizarro, Ainhoa and Desviat, Lourdes R},
  title = {Exploring RNA therapeutics for urea cycle disorders},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2024},
  volume = {47},
  number = {6},
  pages = {1269--1277},
  doi = {10.1002/jimd.12807}
}
Kostenlos starten →